INSIGHTS BRIEF
Obesity Treatment Rates Increase as GLP-1 Inhibitors Prosper
IQVIA Forecast Link
Mar 17, 2023

Obesity is a top cause of premature death, with 2.8 million deaths each year linked to excess weight.1 It is a complex problem, but there are prevention options and new pharmaceutical treatments available. IQVIA's Forecast Link expects GLP-1 inhibitor sales to surpass $17bn by 2031. Patient Link calculates that only 2% of people with obesity are currently receiving prescription drug treatment, with an estimated 3.1 million patient pool available across seven major markets in 2022.

Please fill in your details on the left to download the article.

Related solutions

Contact Us